# Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

> **NCT04143906** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04143906
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143906, "Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04143906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*